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 24 
Abstract 25 
Study question: Are the quantitative and qualitative characteristics of semen samples of patients 26 
with testicular cancer (TC), prior to anticancer therapy, different from infertile oligozoospermic 27 
and normozoospermic age-matched men? 28 
Summary answer: Sperm concentration in TC patients was significantly decreased with no 29 
difference in estimated numerical chromosome aberrations and nuclear decondensation compared 30 
to normozoospermic men, while the infertile, oligozoospermic men had significantly poorer 31 
sperm qualitative characteristics versus the TC group overall and oligozoospermic patients with 32 
testicular cancer. 33 
What is known already: Spermatogenesis is altered in TC patients at the time of the diagnosis. 34 
However, the mechanism responsible for the decreased semen quantity in patients with testicular 35 
cancer is not well understood. Anticancer treatment may have gonadotoxic side effects and post 36 
treatment fertility cannot be predicted. Before commencing anticancer treatment, 37 
cryopreservation may be suggested to preserve fertility but there are no data regarding the risk of 38 
genetic aberrations in these sperms. 39 
Study design, size, duration: This is a cross-sectional study examining semen from 28 patients 40 
with testicular cancer, 20 oligozoospermic and 20 normozoospermic age-matched men attending 41 
the Andrology Center and the Sperm Cryopreservation Laboratory of the Medical and Health 42 
Science Center, University of Debrecen. Semen samples from patients with testicular cancer were 43 
collected after orchidectomy, but prior to anticancer treatment. Semen samples from TC patients 44 
recruited over a period of 4 years were studied. Based on their sperm concentration, TC patients 45 
were subgrouped into an oligozoospermic TC (TCO) and a normozoospermic TC (TCN) group. 46 
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For statistical analysis, the normal group (NZ+IO) comprised non-tumorous normozoospermic 47 
(NZ) and infertile oligozoospermic (IO) men. 48 
Participants/materials/setting, method:  49 
The ejaculates were assessed as per World Health Organization guidelines. Hyaluronic acid (HA) 50 
binding capacity was the functional test. To determine the numerical chromosome aberrations we 51 
used multicolour fluorescence in-situ hybridization. Aniline blue (AB) staining was performed as 52 
a nuclear decondensation marker test.  53 
Main results and the role of chance:  54 
The results did not reveal any significant difference in disomy of sex chromosomes and 55 
chromosome 17, diploidy and estimated numerical chromosome aberrations and AB staining 56 
results upon comparing the normozoospermic and testicular cancer groups, although the sperm 57 
concentration (p<0.001) and HA binding capacity (p<0.001) were lower in the TC group. 58 
Estimated numerical chromosome aberrations (p<0.001), AB staining (p<0.001) and HA-binding 59 
capacity (p=0.019) was lower in the infertile, oligozoospermic group as compared to the patients 60 
with testicular cancer.  The TCO group had significantly better results in every examined 61 
parameter than the infertile, oligozoospermic group.  62 
In the non-tumorous control group (NZ+IO), a significant (p<0.001) correlation (Spearman’s 63 
rho=r) was found between sperm concentration and aneuploidy rate (r=-0.642), AB staining (r=-64 
0.876) and HA binding (r=0.842); the HA-binding capacity was related to the aneuploidy rate 65 
(r=-0.678) and the AB staining (r=-0.811,); and there was significant correlation between 66 
aneuploidy and AB staining (r=0.559). In the TC group, apart from the negative correlation 67 
between sperm concentration and estimated chromosomal aberrations (r=-0.642), no other 68 
correlations were observed. 69 
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Limitations, reasons for caution: Data on confounders influencing sperm characteristics, such 70 
as smoking, occupational or environmental hazards, alcoholism, co-morbidities and other 71 
andrological conditions, were not collected.  72 
Wider implications of the findings: This is the first study to demonstrate that sperm qualitative 73 
characteristics in anticancer therapy naïve oligozoospermic TC patients differ significantly from 74 
those in infertile oligozoospermic men and do not differ from those in normozoospermic men. 75 
Our results need to be validated in similar groups of men and in other patient groups with cancer 76 
where cryopreservation is advisable.  77 
Study funding/competing interest(s): This research was supported by the European Union and 78 
the State of Hungary, co-financed by the European Social Fund in the framework of TÁMOP-79 
4.2.4.A/2-11/1-2012-0001 ‘National Excellence Program’. The authors have no conflict of 80 
interest to declare. 81 
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 87 
Introduction 88 
Testicular germ cell carcinoma (TC) represents about 1% of malignant tumors in men, but is the 89 
most frequent solid tumor in men aged 15-35 years. The majority of patients with testicular 90 
cancer are diagnosed prior to conception of the first offspring (de Kretser, 2000). The use of 91 
chemo- and radiotherapy combined with surgery has resulted in increased survival rates, i.e. over 92 
95% 5-year survival rate (Kliesch et al., 1997).  93 
Chemotherapeutic agents and radiotherapy are both known to be gonadotoxic (Howell and 94 
Shalet, 2001; Lass et al., 2001) and may lead to defective sperm production resulting in 95 
oligozoospermia, severe oligozoospermia and even azoospermia, and as a consequence infertility 96 
(Hallak et al., 1999). Since the majority of men treated for testicular carcinoma are in their 97 
reproductive years, the long-term therapy associated side effects are of increasing importance. 98 
Although, the recovery of spermatogenesis depends on the treatment modality, dose and 99 
individual susceptibility, the extent of recovery after treatment is difficult to predict (Gandini et 100 
al., 2003). Therefore, sperm cryopreservation is recommended for patients with testicular cancer 101 
preceding treatment. 102 
An increasing number of reports suggest that spermatogenesis may already be defective at the 103 
time of diagnosis of TC (Martin et al., 1997; Hallak et al., 1999; Gandini et al., 2003; Agarwal 104 
and Allamaneni, 2005; van Casteren et al., 2007; Dohle, 2010; Rives et al., 2012). It remains 105 
unclear whether the etiology of oligozoospermia in most TC patients arises from testicular 106 
alteration due to the presence of malignancy or surgical removal, or as a result of the altered 107 
neuroendocrine environment (Spermon et al., 2006). Although sperm cryopreservation is widely 108 
advocated, the seminal genetic alterations, functional characteristics and fertilization potential of 109 
TC patients has not been intensively investigated (Alvarez et al., 1999; Spermon et al., 2006). 110 
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The developing spermatids undergo complex changes during spermiogenesis in both the nuclear 111 
and cytoplasmic compartments; this includes meiosis, histone to protamine replacement, 112 
acrosome development, sprouting of the sperm tail and cytoplasmic extrusion (Kovanci et al., 113 
2001). In addition, there is a remodelling of the sperm plasma membrane during late 114 
spermiogenesis, a step that facilitates formation of the zona pellucida and hyaluronic acid (HA) 115 
binding sites (Huszar et al., 2003; Jakab et al., 2005; Huszar et al., 2007). It has been previously 116 
proven by assays of cytoplasmic and nuclear biochemical markers that mature sperm selectively 117 
bind to solid state HA (Jakab et al., 2005). We used this functional feature of sperm to examine 118 
fertilization potential (HA binding assay).  119 
With maturation of the sperm there is increase in protamine at the expense of histones. Aniline 120 
blue (AB) staining is an efficient dye to detect histones, and its negative staining certifies sperm 121 
maturity. Previous studies have reported an association between diminished histone to protamine 122 
exchange, as detected by AB staining, of excess persistent histones in the nuclear compartment of 123 
sperm with arrested cellular maturity (Foresta et al., 1992; Agarwal and Said, 2003; Sati et al., 124 
2008). Additionally, it has been demonstrated that chromatin condensation is impaired not only 125 
in malformed but also in morphologically normal spermatozoa (Hofmann and Hilscher, 1991). 126 
We used AB staining to detect sperm nuclear condensation. 127 
Knowing that aberrant sperm have an increased frequency of chromosomal aneuploidies 128 
(McAuliffe et al., 2012), we investigated sperm aneuploidy frequencies of chromosome 17, X 129 
and Y using multi-colour fluorescence in-situ hybridization (FISH).  130 
Fertility in TC patients has not been extensively evaluated. Although the classical semen analysis 131 
is the gold standard for male fertility assessment as it provides quantitative information on the 132 
semen status of men, it is also important to investigate the qualitative characteristics suggestive 133 
of sperm damage in men with testicular cancer (Cooper et al. 2010; van der Steeg et al. 2011; 134 
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Mallidis et al. 2012). It is also not clear whether the cancer itself or the triggering factors of 135 
cancer per se induce changes in genomic integrity of the spermatozoon.  136 
The aim of the present study is to evaluate the quality of semen in patients with testicular cancer 137 
before treatment for cancer. We used conventional and specific tests to determine the quantitative 138 
and qualitative changes in the ejaculated spermatozoa at diagnosis of testicular cancer and 139 
compared these findings to age-matched groups of infertile oligozoospermic and 140 
normozoospermic men.  141 
142 
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 143 
Materials and Methods  144 
Patients 145 
Patients with testicular cancer We examined semen samples of 28 postorchidectomy patients with 146 
TC, who were referred for semen cryopreservation before the initiation of any adjuvant radio- or 147 
chemotherapy, to the Andrology Laboratory of the Department of Obstetrics and Gynecology, 148 
Medical and Health Science Center, University of Debrecen.  149 
Infertile oligozoospermic men (IO) 150 
Semen samples of 20 age-matched infertile men referred for semen analysis to the Andrology 151 
Laboratory were also studied.  152 
Normozoospermic men (NZ) 153 
Twenty healthy age-matched sperm donors with normal sperm characteristics were also studied.  154 
Ethical approval 155 
Prior to the study, all patients and controls were given detailed information about the aims and 156 
procedures of the present investigation and written informed consent was obtained. The author’s 157 
respective institutional ethics review board approved the study protocol (reference number: 158 
DEOEC RKEB/IKEB: 2736/2008 and 2976/2012-EHR).  159 
Semen analysis 160 
Semen specimen was collected after a requested abstinence of two to four days. Semen analysis 161 
was performed manually according to the World Health Organization guidelines (WHO, 2010) 162 
(Table I.).  163 
FISH analysis 164 
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Smears of semen samples (10 μL) were fixed with methanol: acetic acid (3:1) for 10 min, air 165 
dried, dehydrated in a series of 70, 85 and 98% ethanol for 2 min each, and stored at – 20 C until 166 
FISH was performed.  167 
For decondensation, the sperm slides were warmed to room temperature, and in order to render 168 
the sperm chromatin accessible to DNA probes, they were treated first with 10 mmol/L 169 
dithiothreitol (Sigma, St. Louis, MO, USA) in 0.1 mol/L Tris-HCl, pH 8.0, for 30 min, then with 170 
10 mmol/L lithium diidosalicylate (Sigma, St. Louis, MO, USA) in Tris-HCl for 1-3 h. After 171 
decondensation, the sperm slides were dehydrated in a series of 70, 85 and 98 % ethanol. The 172 
sperm FISH was performed using three FISH probes: alpha-satellite sequence specific 173 
centromeric probes for chromosome 17 (D17Z1, SpectrumAqua), X (DXZ1, SpectrumOrange) 174 
and Y (DYZ1, SpectrumGreen) (Abbott/Vysis, Des Plaines, IL, USA). 175 
The sample and the probe denaturation were carried out at 76C for 3 min. The hybridization was 176 
carried out at 37C in a moist chamber for 16-18 h (Hybrite, Abbott/Vysis, Des Plaines, IL, 177 
USA). Post hybridization washes were performed with 50% formamide/ 2X saline sodium citrate 178 
(SSC) at 42 C for 15 min. The slides were then washed with 2X SSC at room temperature for 10 179 
min and 2X SSC/ 0.1 % NP-40 for 5 min. After washing, the nuclei were counterstained with 4’- 180 
6’ diamidino-2 - phenylindole (DAPI) (Abbott/Vysis, Des Plaines, IL, USA).  181 
The sperm FISH analysis was carried out by scoring a minimum of 5 000 sperm heads. The 182 
overall hybridization efficiency was >98%. Nuclei that overlapped or displayed no signal due to 183 
hybridization failure were omitted from the scoring. A spermatozoon was considered disomic 184 
when it showed two fluorescence signals of the same color, comparable in size and brightness in 185 
the same focal plane, positioned inside the sperm head and at least one signal apart. Scoring was 186 
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performed using a Zeiss Axioplan2 (Carl Zeiss, Jena, Germany) fluorescence microscope, and the 187 
images were captured and analyzed by ISIS software (Metasystems, Althussheim, Germany). 188 
We chose chromosome 17 as its aneuploidy frequency matches the average aneuploidy of all 189 
autosomal chromosomes (i.e., 0.12%) (Downie et al., 1997; Egozcue et al., 1997,  Jakab et al., 190 
2003, Jakab et al., 2005, Mokanszki et al, 2012).  191 
The sperm disomy frequencies and estimated numerical chromosome aberrations were calculated 192 
as described previously (Egozcue et al., 1997). 193 
Sperm HA-binding assay 194 
The semen sample was maintained at room temperature (18-28˚C) for 30 to 60 minutes to allow 195 
it to liquefy. The HA-binding test (MidAtlantic Diagnostics, Martlon, NJ, USA) was carried out 196 
at room temperature: the sample was mixed and 10 μL was pipetted onto the center of the 197 
chamber. The CELL-VU gridded cover slip was placed over the chamber, taking care to avoid air 198 
bubble formation. As per the protocol, the chamber was incubated at room temperature for at 199 
least 10 minutes, but not more than 20 minutes this period proved to be necessary for sperm to 200 
bind to HA. The number of bound, motile sperm and total, motile sperm was scored. The ratio of 201 
HA binding motile sperm was calculated as follows: %Bound = 100 X Bound Motile / Total 202 
Motile.  203 
AB staining of the sperm head 204 
The slides were stained by 5% AB solution (Sigma Co., St. Louis, MO, USA) acidified to 205 
approximately pH 3.5 with acetic acid for 5 minutes, and then washed with tap water and allowed 206 
to completely air dry at room temperature (Huszar et al., 2003). Mature spermatozoa, having 207 
completed histone-protamine replacement, stained very lightly with AB (light=mature 208 
spermatozoa). The slightly immature spermatozoa were stained more extensively (intermediate= 209 
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diminished maturity), and immature spermatozoa with substantial degrees of persistent histones 210 
were darkly stained (dark=immature spermatozoa). For each stained smear, 200 spermatozoa 211 
were evaluated under a light microscope in oil immersion magnification (100 x objectives). 212 
Spermatozoa with unstained nuclei were considered normal while those AB stained 213 
(intermediate+dark) considered abnormal. The results were expressed as percentages of stained 214 
and unstained sperm. An ejaculate with a rate of blue-stained sperm <20% was considered 215 
normal (Sellami et al., 2013). 216 
Statistical analysis 217 
Kolmogorov-Smirnov test was used for the evaluation of the normality of the data. Most 218 
parameters were non-normally distributed therefore analyses were performed by Mann-Whitney 219 
U test. The Spearman’s rho was calculated for correlation analysis. A value of p<0.05 was 220 
considered statistically significant. All analyses were performed with the SPSS Statistics 221 
software, version 22.0 (IBM Corps., Armonk, NY, USA). 222 
 223 
224 
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 225 
Results 226 
Patients with testicular cancer 227 
Mean age of the TC patients was 28.9 years (range: 18-47 years), and mean sperm concentration 228 
was 27.7 x10
6
/mL (range: 6-65 x10
6
/mL) (Table I., Table II.). Patients were grouped as per 229 
sperm concentration as being oligozoospermic (TCO) (sperm concentration <15 x10
6
/mL) or 230 
normozoospermic (TCN) (sperm concentration ≥15 x106/mL). The histological subtype of tumor 231 
was also used to further subgroup the patients (i.e., seminoma (n=16) and non-seminoma (n=12)). 232 
Investigation of chromosome numerical aberrations by FISH 233 
The results of the FISH analysis are presented in Table II. In the 68 individuals, we evaluated a 234 
total of 342 000 spermatozoa, i.e., on average 5 030 sperms per patient. 235 
The X/Y ratios were close to 1:1 in all groups. Higher sex and 17 chromosome disomy 236 
frequencies in the IO group as compared to the normozoospermic and TC groups, resulted in 237 
significant differences in estimated numerical chromosome aberrations. A significant difference 238 
was observed in the frequency of estimated numerical chromosome aberrations between IO and 239 
NZ (p<0.001), IO and TC (p<0.001), IO and TCO (p=0.008) and IO and TCN (p<0.001) groups; 240 
no significant differences were found between the normozoospermic and TC, TCO and TCN, NZ 241 
and TCN, and NZ and TCO groups (Table II.)   242 
Upon comparing the NZ group with the TCO group, we found no significant difference in sex 243 
chromosome disomy, chromosome 17 disomy, and estimated chromosome aberration 244 
frequencies. 245 
Sperm HA binding assay results 246 
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The mean sperm HA-binding capacity of the motile spermatozoa was 81.1% in the 247 
normozoospermic group, 41.9% in the oligozoospermic group, 56.9% in the testicular cancer 248 
group, 60.9% in the TCN and 46.8% in the TCO group. The HA-binding capacity of the 249 
normozoospermic men proved to be significant higher than the oligozoospermic (p<0.001) and 250 
the testicular cancer group (p<0.001). The oligozoospermic group had significant lower HA-251 
binding capacity than the testicular cancer group (p=0.019). The difference was significant 252 
between the IO and TCO (p=0.007), NZ and TCN (p<0.001), and NZ and TCO (p=0.001) 253 
groups, but not between the TCO and TCN, and IO and TCN groups. (Table II.) 254 
In the normozoospermic group, only 2 (10%) semen samples had HA-binding capacity below the 255 
clinical cut-off of <60%, i.e., 55% and 58%, with a sperm concentration of 26x10
6
/mL and 256 
30x10
6
/mL, respectively. In the oligozoospermic group, 16 samples (80%) had low HA-binding 257 
capacity, and 10 (35.7%) of the TC samples had HA-binding capacity under 60%.  258 
AB staining results 259 
We evaluated a total of 15 564 spermatozoa from 68 individuals, i.e, 229 per patient on average. 260 
The mean proportion of AB stained sperms was 16.9% in the normozoospermic group, 45.7% in 261 
the oligozoospermic group, 23.0% in the TC group, 19.9% in the TCN group and 30.7% in the 262 
TCO group (Table II). 263 
The difference in AB staining was found to be significant between the IO and NZ (p<0.001), IO 264 
and TC (p<0.001), IO and TCO (p<0.001), TCO and TCN (p=0.028), NZ and TCN (p=0.005), 265 
and IO and TCN (p=0.011) groups. There was no difference between NZ and TC, and NZ and 266 
TCO groups (Table II). 267 
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Among the 20 normozoospermic men, 2 (10%) had more than 20% AB-stained cells i.e., 48.6% 268 
and 24.6% with sperm concentration of 18x10
6
/mL and 26 x10
6
/mL, respectively. All the 269 
oligozoospermic patients had higher than normal AB-stained sperm proportion (28-68%). In the 270 
testicular cancer group, the percentage of AB stained sperm was 5-53%. Normal results were 271 
found in 17 (60.7%) of the TC patients.  272 
Histological findings 273 
The TC group was further divided into two subgroups according to the histological subtype of the 274 
testicular tumor, seminoma (n=16) and non-seminoma (n=12) groups. We did not find any 275 
significant differences between the two groups regarding age (30.4 versus 27.1 years; p=0.16), 276 
sperm concentration (31.4 versus 22.7x10
6
/mL; p=0.226), X/Y ratio (1.05 versus 1.1; p=0.982), 277 
sex chromosome disomy (0.37 versus 0.4; p=0.214), chromosome 17 disomy (0.07 versus 0.1; 278 
p=0.599), total diplody (0.14 versus 0.2; p=0.19), estimated chromosome aberration frequencies 279 
(3.86 versus 3.93; p=0.239), HA-binding capacity (57 versus 57%; p=0.45) and the AB stained 280 
proportion of cells (21 versus 26%; p=0.133). 281 
Correlation analyses between sperm concentration, HA-binding capacity, estimated numerical 282 
chromosome aberrations and AB staining 283 
For correlation analysis, the IO and NZ men together constituted a control group. Correlation 284 
analysis was performed for the different parameters in the above defined control group and the 285 
TC group. In the control group, a statistically significant (p<0.001) correlation was found 286 
between sperm concentration and HA-binding capacity (Spearman’s rho =0.842), estimated 287 
chromosomal aberrations (Spearman’s rho=-0.642) and AB stained proportion of cells 288 
(Spearman’s rho=-0.876); estimated numerical chromosome aberrations and HA-binding 289 
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capacity (Spearman’s rho=-0.678) and AB stained cells (Spearman’s rho=0.559); HA-binding 290 
capacity and AB stained proportion of cells (Spearman’s rho=-0.811) (Figure I.). 291 
In the TC group, we found a significant correlation only between the sperm concentration and 292 
estimated chromosomal aberrations (Spearman’s rho=-0.642). No other significant correlations 293 
were observed between the other parameters examined. 294 
295 
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 296 
Discussion 297 
To the best of our knowledge, this is the largest study to date which has investigated the 298 
pretreatment semen parameters of patients with testicular cancer, using not only conventional test 299 
(sperm concentration), but also evaluating the sperm integrity at multiple levels, i.e., membrane 300 
remodeling (HA-binding assay), nuclear condensation (AB staining) and numerical chromosome 301 
aberrations (FISH). Furthermore, to evaluate the cancer effect on semen quality, we compared the 302 
semen characteristics of patients with testicular cancer to infertile oligozoospermic men and 303 
normozoospermic men. In addition, we examined the correlation of numerical chromosomal 304 
aberrations, and functional and structural characteristics of semen in the non-cancer 305 
(normozoospermic and oligozoospermic men) and testicular cancer group. We also analyzed 306 
whether the histological subtype of testicular cancer influenced spermiogenesis. 307 
The present study did not reveal any significant difference regarding X/Y ratio, disomy of sex 308 
chromosomes and chromosome 17, diploidy and estimated numerical chromosome aberrations 309 
between the normozoospermic and testicular cancer groups, although sperm concentration, HB 310 
capacity and AB staining results were significantly lower in TC group. Further, aneuploidy rate 311 
and AB staining results for oligozoospermic TC patients did not differ from those of 312 
normozoospermic men. Significant difference between the TCO and TCN group was found only 313 
in sperm concentration and AB staining. In every examined parameter there was a significantly 314 
lower value in the infertile, oligozoospermic group as compared to patients with testicular cancer. 315 
Even the TCO group had significantly better results than the infertile, oligozoospermic group. 316 
In the control group of men without cancer (NZ+IO), significant correlation was found between 317 
sperm concentration and aneuploidy rate, AB staining and HA binding; the HA-binding capacity 318 
was related to the aneuploidy rate and the AB staining. There was significant, but weaker 319 
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correlation between aneuploidy and AB staining, and this may well be explained by a previous 320 
report that the degree of condensation affects the efficacy of the hybridization at FISH, as 321 
reported in a double probing study (Ovari et al., 2010). Our correlation findings support a 322 
previous study, and perhaps confirm that in men without cancer sperm concentration, aneuploidy 323 
frequency, nuclear condensation and fertilization potential detected by HA binding capacity are 324 
related characteristics of the semen (Mokanszki et al, 2012; Pylyp et al. 2013). In contrast, in the 325 
testicular cancer group, with an exception of a significant correlation between sperm 326 
concentration and estimated numerical chromosome aberration, no correlations were found 327 
between the other studied parameters. This finding may suggest that sperm concentration per se 328 
cannot predict the quality of the sperm of the patients with testicular cancer. This assumption 329 
definitely deserves further investigation. 330 
Recently, it has been hypothesized that a common defect is implicated in the pathogenesis of 331 
testicular cancer and decreased spermatogenesis (e.g. testicular dysgenesis syndrome) (Jacobsen 332 
et al., 2000). A possible explanation for the differences in the sperm concentration found between 333 
the TC and the NZ groups may be the intratesticular (tumor generated local inflammation, 334 
elevation of inflammatory markers and other factors, local tissue trauma due to the orchidectomy) 335 
and environmental (stress of treatment) factors to which the TC patients are exposed. As a result 336 
the TC patients’ quantitative aberrations don’t necessarily go hand-in-hand with qualitative 337 
abnormalities, e.g., sperm aneuploidy and integrity. Furthermore, it has been reported that in 338 
testicular regions closer to the cancer site, spermatogenesis is affected more severely as compared 339 
to more distant parts of the testis (Berthelsen JG and Skakkebaek, 1983). Carcinoma in situ (CIS) 340 
in seminiferous tubules at the periphery of germ cell tumors may be an underlying cause of 341 
deteriorating semen quality. Contralateral CIS in testicular germ cell tumors was found in 5% of 342 
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patients, and CIS was significantly associated with poor spematogenesis and testicular atrophy 343 
(Daugaard G et al., 1992; Dieckmann et al., 2007).  344 
It has been reported that patients with malignancy have poor sperm quality prior to anticancer 345 
treatment (Meirow et Schenker, 1995; Hallak et al., 1999; Gandini et al., 2003; Trottmann et al., 346 
2007, Molnar et al., 2014). In a Dutch study (van Casteren et al., 2010), 764 male cancer 347 
patients’ semen samples were evaluated: 64% of the samples were abnormal, and men with 348 
testicular germ cell cancer (n=292) had the lowest sperm concentrations. In our study cohort, 349 
although significantly lower than the NZ group, the mean sperm concentration (27.7x10
6
/mL) in 350 
the TC group was above the WHO (2010) reference value. The French National study published 351 
data on 1158 men with testicular cancer. Here the diagnosis of azoospermia and the percentage of 352 
severe oligozoospermia were independent of tumor histological type and disease stage. However, 353 
sperm concentration and total sperm number were significantly lower at stage III independent of 354 
histological type. This suggests that the tumor size may influence spermatogenesis (Rives et al., 355 
2012). 356 
The only established method to preserve fertility in male cancer patients before gonadotoxic 357 
anticancer treatment is semen cryopreservation, which may be used in assisted reproduction 358 
techniques (ART). Our results suggests that semen samples dedicated for cryopreservation from 359 
TC patients, before the initiation of chemotherapy or irradiation, do not carry an elevated risk for 360 
numerical chromosome aberrations, even if the sample is oligozoospermic. Furthermore, we 361 
observed that the oligozoospermic and normozoospermic samples of patients with testicular 362 
cancer did not differ qualitatively. This may explain the 33-56% success rate of ART procedures 363 
using banked semen from cancer patients (van Casteren et al., 2008; Dohle, 2010). Additionally, 364 
it has been reported that cryopreservation does not affect the frequency of chromosomal 365 
abnormalities or alter the sex ratio in human sperm (Martin el al., 1991). 366 
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One previous study (Tempest et al., 2007) compared sperm aneuploidy, using multicolour FISH, 367 
in 5 patients with testicular cancer before treatment with healthy normozoospermic donors but 368 
did not enumerate the estimated numerical chromosomal aberrations. Our study, on the other 369 
hand, not only recruited a larger number of patients with testicular cancer before treatment 370 
(n=28), but also compared them with a normozoospermic and an oligozoospermic group. 371 
Although it is unclear whether malignancy per se can adversely affect the genomic integrity of 372 
sperm, our findings support a previous study where no significant difference in sperm DNA 373 
fragmentation was found upon comparing 98 men diagnosed with cancer and healthy sperm 374 
donors (McDowell et al., 2013). Different tests are available to evaluate sperm DNA 375 
fragmentation, i.e., the acridine orange staining test, the sperm chromatin structural assay 376 
(SCSA), terminal deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL), and the 377 
comet assay. Ståhl et al (2006) investigated sperm DNA integrity in patients with testicular 378 
cancer using SCSA and TUNEL and their results suggest, in agreement to our observations, that 379 
the use of cryopreserved semen carries no increased risk of transmitting damaged DNA to 380 
offspring. Yagci et al (2010) found good agreement between the HA bound fraction of sperm and 381 
high DNA integrity as detected by acridine orange staining method. This study demonstrated that 382 
testing with the sperm HA-binding assay does reflect the proportion of sperm with high DNA 383 
integrity (Yagci et al., 2010). 384 
In our study, the HA binding capacity was decreased in the TC group compared to the 385 
normozoospermic group. Furthermore, in the patient group the HA-binding capacity did not 386 
correlate with sperm concentration. As such, it may be speculated that sperm function and 387 
fertilization potential cannot be estimated by sperm concentration in cancer patients. 388 
Additionally, the low sperm concentration and HA-binding capacity in TC patients may not 389 
necessarily suggest a higher aneuploidy frequency and decreased nuclear condensation.  390 
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We found that AB stained cell proportion was not significantly different between the 391 
normozoospermic and TC groups, but was significantly higher in the IO group, as compared to 392 
the other two groups. It is known that a higher and lower proportion of AB stained sperms is 393 
associated with recurrent pregnancy loss (Ruixue et al., 2013) and fertility, respectively (Auger et 394 
al., 1990, Agarwal and Said, 2003). A recent study examined human sperm vacuoles and found 395 
that their presence is associated with failure of chromatin condensation as detected by AB 396 
staining (Boitrelle et al., 2013). It has been demonstrated (Huszar et al., 2003; Jakab et al., 2005) 397 
that mature sperms that undergo plasma membrane remodeling and are able to bind to solid state 398 
HA, present no persistent histones or increased frequency of chromosomal aneuploidies.  399 
Molecular components of sperm, as biomarkers of testicular damage, have the potential to be 400 
important indicators of reproductive toxicity. Measurement of messenger ribonucleic acid 401 
(mRNA) alterations may serve as one option in this regard (Dere et al. 2013). Furthermore, sperm 402 
proteomics-based studies have explored the potential diagnostic biomarkers of 403 
asthenozoospermia (Siva et al., 2010). Additionally, studies into the molecular basis of epigenetic 404 
regulation may help in understanding spermiogenesis further (Dere et al., 2013,). Another study 405 
presents maternally imprinted gene methylation as a new biomarker in andrology, where 406 
correlation with clinical parameters was also found (Kläver et al., 2013). 407 
Limitations of our study include lack of data on confounders influencing sperm characteristics 408 
such as smoking, occupational or environmental hazards. Co-morbidities and other andrological 409 
conditions were not studied. 410 
This is the first study to demonstrate that sperm qualitative characteristics in cancer therapy-naïve 411 
oligozoospermic TC patients differ significantly from those in infertile oligozoospermic men and 412 
do not differ from those in normozoospermic men. Our results definitively need to be validated in 413 
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further studies of similar groups of patients and in patients with other types of tumor where 414 
cryopreservation is advisable. 415 
 416 
417 
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Legend of figure 431 
Figure 1. Correlation analysis was performed between the sperm concentration, hyaluronic acid 432 
(HA) binding capacity, estimated chromosome aberrations and aniline blue (AB) staining in the 433 
control group (normozoospermic men (n=20) + infertile, oligozoospermic men (n=20)). 434 
Spearmen’s rho was calculated, p<0.005 was considered as statistically significant result. 435 
436 
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